Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $71.0 million.

  • Myriad Genetics' Cost of Revenue rose 157.37% to $71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $284.1 million, marking a year-over-year decrease of 1303.95%. This contributed to the annual value of $284.1 million for FY2024, which is 176.35% down from last year.
  • Myriad Genetics' Cost of Revenue amounted to $71.0 million in Q3 2025, which was up 157.37% from $71.9 million recorded in Q2 2025.
  • Myriad Genetics' Cost of Revenue's 5-year high stood at $118.7 million during Q4 2022, with a 5-year trough of $44.1 million in Q1 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $59.2 million (2023), whereas its average is $65.2 million.
  • Per our database at Business Quant, Myriad Genetics' Cost of Revenue plummeted by 4455.21% in 2021 and then surged by 15917.03% in 2022.
  • Over the past 5 years, Myriad Genetics' Cost of Revenue (Quarter) stood at $45.8 million in 2021, then skyrocketed by 159.17% to $118.7 million in 2022, then fell by 3.45% to $114.6 million in 2023, then plummeted by 37.17% to $72.0 million in 2024, then fell by 1.39% to $71.0 million in 2025.
  • Its last three reported values are $71.0 million in Q3 2025, $71.9 million for Q2 2025, and $69.2 million during Q1 2025.